A Review on Comparison of Allopathic Medicines to other Drug Therapies in the Management of Asthma


Cite item

Full Text

Abstract

Asthma, is a chronic disease of the airways and is characterized by exacerbations of bronchospasm and noticeable airway inflammation. Current asthma therapy has emerged from naturally occurring compounds through rational pharmaceutical advancements, and it is very beneficial. In this review, we have discussed the different drug therapies i.e., Ayurvedic, Homeopathic, Unani, and Allopathic affecting asthma treatment. Allopathic medicines are used as a controller medication for regular maintenance of asthma i.e., long-acting β-agonists, inhaled corticosteroids, anti-leukotriene medicines, and novel biologic agents. Pharmacological research is more important in generating effective, long-lasting, and safe asthma treatments, but it has been difficult to produce new classes of anti-asthmatic therapies. A combination inhaler that contains a long-acting β2-agonist and a corticosteroid is currently the \"gold standard\" for treating asthma. Allopathic treatments for asthma have been proven effective in reducing the probability of asthma attacks and for improving symptoms along with lung functions as compared to other therapies. The level of asthma management and the possible risk of future worsening are used to determine the treatment's strategies. This review article describes the comparison of allopathic therapy of asthma with homeopathy, ayurvedic and Unani system and gives justification supported by a number of case studies for being allopathic, a better therapy when compared with others.

About the authors

Ruchika Garg

School of Pharmacy, Maharaja Agrasen University

Author for correspondence.
Email: info@benthamscience.net

Mona Piplani

School of Pharmacy, Maharaja Agrasen University

Email: info@benthamscience.net

Ashutosh Upadhayay

NIMS Institute of Pharmacy, NIMS University Rajasthan

Email: info@benthamscience.net

Yogendra Singh

School of Pharmacy, Maharaja Agrasen University

Email: info@benthamscience.net

Pankaj Bhateja

School of Pharmacy, Maharaja Agrasen University

Email: info@benthamscience.net

References

  1. Panda A, Doddanagali SR. Clinical efficacy of herbal Padmapatradi yoga in bronchial asthma (Tamaka Swasa). J Ayurveda Integr Med 2011; 2(2): 85-90. doi: 10.4103/0975-9476.82522 PMID: 21760694
  2. Behera D. Bronchial asthma. New Delhi: Jaypee Brothers 2000.
  3. Bielory L, Lupoli K. Herbal interventions in asthma and allergy. J Asthma 1999; 36(1): 1-65. doi: 10.3109/02770909909065150 PMID: 10077136
  4. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17(1): 1-12. doi: 10.1016/0197-2456(95)00134-4 PMID: 8721797
  5. Huntley A, Ernst E. Herbal medicines for asthma: A systematic review. Thorax 2000; 55(11): 925-9. doi: 10.1136/thorax.55.11.925 PMID: 11050261
  6. Boly R, Yabre Z, Nitiema M, et al. Pharmacological evaluation of the bronchorelaxant effect of waltheria indica L. (Malvaceae) extracts on rat trachea. Evid Based Complement Alternat Med 2021; 2021: 1-8. doi: 10.1155/2021/5535727 PMID: 33995545
  7. Kasirajan B, Maruthamuthu R, Gopalakrishnan V, et al. A database for medicinal plants used in treatment of asthma. Bioinformation 2007; 2(3): 105-6. doi: 10.6026/97320630002105 PMID: 18288333
  8. Kumar GL, Mahendra S, Richa S, Rajesh D. Pharmaceutico analytical study and comparative antimicrobial effect of hartalabhasma and hartalagodantibhasma. Int J Ayurveda Pharma Res 2013; 1(3): 36-46.
  9. Singh BB, Khorsan R, Vinjamury SP, Der-Martirosian C, Kizhakkeveettil A, Anderson TM. Herbal treatments of asthma: A systematic review. J Asthma 2007; 44(9): 685-98. doi: 10.1080/02770900701247202 PMID: 17994396
  10. Clarke R, Lundy FT, McGarvey L. Herbal treatment in asthma and COPD - current evidence. Clin Phytosci 2015; 1(1): 4. doi: 10.1186/s40816-015-0005-0
  11. Singh SK, Patel JR, Dubey PK, Thakur S. A review on antiasthmatic activity of traditional medicinal plants. Int J Pharm Sci Res 2014; 5(10): 4097.
  12. Mahammad Y, Mahamad I. Anti histaminic herbal drugs: A review. Int J Pharm Pharm Sci 2010; 2: 28-9.
  13. Srivastava KC. Extract of a spice - Omum (Trachyspermum ammi)-shows antiaggregatory effects and alters arachidonic acid metabolism in human platelets. Prostaglandins Leukot Essent Fatty Acids 1988; 33(1): 1-6. doi: 10.1016/0952-3278(88)90115-9 PMID: 3141935
  14. Paudyal B, Thapa A, Sigdel KR, Adhikari S, Basnyat B. Adverse events with ayurvedic medicines-possible adulteration and some inherent toxicities. Wellcome Open Res 2019; 4: 23. doi: 10.12688/wellcomeopenres.15096.3
  15. Jude S. Ayurvedic and Traditional Systems of Medicine in Clinical Trials: An Overview. In: Chemistry, Biological Activities and Therapeutic Applications of Medicinal Plants in Ayurveda. 2022.
  16. Shah J. Homeopathic remedies. Available from:https://www.practo.com/healthfeed/homeopathic-remedies-for-asthma-26893/post (cited: 18 October 2022)
  17. Jain JP. A clinical trial of Kantakari in cases of tamakswasa (some respiratory diseases). J Res Ayur Siddha 1980; 1: 447-60.
  18. Jaber R. Respiratory and allergic diseases: From upper respiratory tract infections to asthma. Prim Care 2002; 29(2): 231-61. doi: 10.1016/S0095-4543(01)00008-2 PMID: 12391710
  19. Khuda-Bukhsh AR, Roy-Karmakar S, Banerjee A, et al. A follow-up study on the efficacy of the homeopathic remedy arsenicum album in volunteers living in high risk arsenic contaminated areas. Evid Based Complement Alternat Med 2011; 2011: 1-9. doi: 10.1093/ecam/nep122 PMID: 19703926
  20. Arantes S, Candeias F, Lopes O, et al. Pharmacological and toxicological studies of essential oil of Lavandula stoechas subsp. luisieri. Planta Med 2016; 82(14): 1266-73. doi: 10.1055/s-0042-104418 PMID: 27124241
  21. Arora P, Ansari SH, Najmi AK, Anjum V, Ahmad S. Investigation of anti-asthmatic potential of dried fruits of Vitis vinifera L. in animal model of bronchial asthma. Allergy Asthma Clin Immunol 2016; 12(1): 42. doi: 10.1186/s13223-016-0145-x PMID: 27536321
  22. Ahmed N, Zakir M, Alam MA, Javed G, Minhajuddin A. Management of asthma (ḌĪQ Al-Nafas) in unani system of medicine. Int J Health Sci 2022; 13036-54.
  23. Passalacqua G, Bousquet PJ, Carlsen KH, et al. ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol 2006; 117(5): 1054-62. doi: 10.1016/j.jaci.2005.12.1308 PMID: 16675332
  24. Garg R, Dobhal K, Saklani T, et al. Covid-19: A challenge towards the sustainability of health in platform era. J Pharm Negat Results 2022; 1666-78.
  25. Dobhal K, Ghildiyal P, Ansori ANM, Jakhmola V. An international outburst of new form of monkeypox virus. J Pure Appl Microbiol 2022; 16 (Suppl. 1): 3013-24. doi: 10.22207/JPAM.16.SPL1.01
  26. Berezin AA. Isotopical positional correlations as a possible model for Benveniste experiments. Med Hypotheses 1990; 31(1): 43-5. doi: 10.1016/0306-9877(90)90053-H PMID: 2314323
  27. Dorsch W, Stuppner H, Wagner H, Gropp M, Demoulin S, Ring J. Antiasthmatic effects of Picrorhiza kurroa: Androsin prevents allergen- and PAF-induced bronchial obstruction in guinea pigs. Int Arch Allergy Immunol 1991; 95(2-3): 128-33. doi: 10.1159/000235416 PMID: 1718906
  28. Boskabady MH, Mohsenpoor N, Takaloo L. Antiasthmatic effect of Nigella sativa in airways of asthmatic patients. Phytomedicine 2010; 17(10): 707-13. doi: 10.1016/j.phymed.2010.01.002 PMID: 20149611
  29. Sagar R, Sahoo HB. Evaluation of antiasthmatic activity of ethanolic extract of Elephantopus scaber L. leaves. Indian J Pharmacol 2012; 44(3): 398-401. doi: 10.4103/0253-7613.96347 PMID: 22701255
  30. McCarney RW, Linde K, Lasserson TJ. Homeopathy for chronic asthma. Cochrane Database Syst Rev 2004; 2004(1): CD000353. doi: 10.1002/14651858.CD000353.pub2
  31. Anagnostatos GS. Small water clusters (clathrates) in the preparation process of homoeopathy. In: Ultra high dilution: Physiology and physics. Dordrecht: Springer 1994.
  32. Van Wassenhoven M. Scientific framework of homeopathy: Evidence-based homeopathy. Int J High Dilution Res 2008; 7(23): 72-92.
  33. Ahmad W, Sofi G, Alam MA, Zulkifle M, Ahmad B. Understanding Holism in the light of principle underlying practice of Unani Medicine. Rev Environ Health 2022; 37(2): 189-99. doi: 10.1515/reveh-2021-0009 PMID: 33984879
  34. Javed A. Asthma treatment in Unani medicines. Available from: https://www.unaniherbal.org/asthma-treatment-in-unani-medicines.html (cited: 25 November 2022)
  35. Naaz F, Khan N. Medical tourism in India: Perspective of Unani medicine. J AYUSH:-Ayurveda, Yoga, Unani Siddha Homeop 2016; 5(3): 52-60.
  36. Itrat M. Methods of health promotion and disease prevention in Unani medicine. J Educ Health Promot 2020; 9(1): 168. doi: 10.4103/jehp.jehp_618_19 PMID: 33015201
  37. Asadi-Samani M, Bahmani M, Rafieian-Kopaei M. The chemical composition, botanical characteristic and biological activities of Borago officinalis: A review. Asian Pac J Trop Med 2014; 7: S22-8. doi: 10.1016/S1995-7645(14)60199-1 PMID: 25312125
  38. Shamsi Y, Khan R, Nikhat S. Clinically significant improvement in a case of bronchial asthma with unani medicine: A case report. Trad Integr Med 2019; 4(3): 130-6. doi: 10.18502/tim.v4i3.1682
  39. Asthma symptoms, prevention and treatment. Available from: https://www.healthline.com/health/asthma#treatmentMelinda (cited: 8 December 2022).
  40. Bronchodialators and corticosteroids. Available from:https://www.nhsinform.scot/tests-and-treatments/medicinesand-medical-aids/types-of-medicine/bronchodilators. (cited: 8 December 2022).
  41. Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev 2020; 72(1): 218-52. doi: 10.1124/pr.119.018150 PMID: 31848208
  42. Asthma news. Long-Term control medications used to treat asthma. Available from: https://getasthmahelp.org/ltc-medications.aspx (cited: 8 December 2022)
  43. Garg R, Piplani M, Singh Y, Joshi Y. Epidemiology, pathophysiology, and pharmacological status of asthma. Curr Respir Med Rev 2022; 18(4): 247-58. doi: 10.2174/1573398X18666220526164329
  44. Jayasinghe H, Kopsaftis Z, Carson K. Asthma bronchiale and exercise-induced bronchoconstriction. Respiration 2015; 89(6): 505-12. doi: 10.1159/000433559 PMID: 26068579
  45. Domingo C, Rello J, Sogo A. As-needed ICS-LABA in mild asthma: What does the evidence say? Drugs 2019; 79(16): 1729-37. doi: 10.1007/s40265-019-01202-0 PMID: 31584145
  46. Kim M. New asthma drug stops attacks. Available from:https://abc30.com/health-watch-asthma-new-drug-medicine/1085397/ (cited: 10 December 2022)
  47. Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma - A narrative review. Eur J Intern Med 2021; 85: 14-22. doi: 10.1016/j.ejim.2021.01.027 PMID: 33563506
  48. Polosa R, Blackburn MR. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharmacol Sci 2009; 30(10): 528-35. doi: 10.1016/j.tips.2009.07.005 PMID: 19762093
  49. Wanke T, Merkle M, Zifko U, et al. The effect of aminophylline on the force-length characteristics of the diaphragm. Am J Respir Crit Care Med 1994; 149(6): 1545-9. doi: 10.1164/ajrccm.149.6.8004311 PMID: 8004311
  50. Vinotha ATS, Ranjani R. A prospective randomized controlled study: Theophylline on oxidative stress and steroid sensitivity in chronic obstructive pulmonary disease patients. Int J Pharm Investig 2017; 7(3): 119-24. doi: 10.4103/jphi.JPHI_58_17 PMID: 29184823
  51. Mattikow MS. Aminophylline improves diaphragmatic contractility. N Engl J Med 1981; 305(22): 1349-50. doi: 10.1056/NEJM198111263052218 PMID: 7290162
  52. Kim LHY, Saleh C, Whalen-Browne A, O’Byrne PM, Chu DK. Triple vs. dual inhaler therapy and asthma outcomes in moderate to severe asthma: A systematic review and meta-analysis. JAMA 2021; 325(24): 2466-79. doi: 10.1001/jama.2021.7872 PMID: 34009257
  53. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996; 334(21): 1380-8. doi: 10.1056/NEJM199605233342107 PMID: 8614425
  54. Sawicki G, Haver K, Wood RA, Redding G, TePas E. Asthma in children younger than 12 years: Initial evaluation and diagnosis. In: UpToDate. 2019.
  55. Springer C, Goldenberg B, Dov I, Godfrey S. Clinical, physiologic, and psychologic comparison of treatment by cromolyn or theophylline in childhood asthma. J Allergy Clin Immunol 1985; 76(1): 64-9. doi: 10.1016/0091-6749(85)90806-1 PMID: 3924984
  56. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5‐lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997; 17((1 Pt 2)): 22S-30S.
  57. Zhang HP, Jia CE, Lv Y, Gibson PG, Wang G. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Allergy Asthma Proc 2014; 35(4): 278-87.
  58. Rachelefsky G. Childhood asthma and allergic rhinitis: The role of leukotrienes. J Pediatr 1997; 131(3): 348-55. doi: 10.1016/S0022-3476(97)80057-1 PMID: 9329408
  59. Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003; 25(10): 2539-52. doi: 10.1016/S0149-2918(03)80315-6 PMID: 14667955
  60. Côté A, Godbout K, Boulet LP. The management of severe asthma in 2020. Biochem Pharmacol 2020; 179: 114112. doi: 10.1016/j.bcp.2020.114112 PMID: 32598948
  61. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 2020; 75(5): 1023-42. doi: 10.1111/all.14221 PMID: 32034960
  62. Ridolo E, Pucciarini F, Nizi MC, Makri E, Kihlgren P, Panella L. Mabs for treating asthma: Omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother 2020; 16(10): 2349-56. doi: 10.1080/21645515.2020.1753440
  63. Mantoan GD. Childhood Asthma Control Intervention through Community Health Workers in the California Central Valley: A Mixed Methods Analysis of Feasibility, and Desirability of Addition of Peer Support. Merced: University of California 2022.
  64. Qiu J, Grine K. Complementary and alternative treatment for allergic conditions. Prim Care 2016; 43(3): 519-26. doi: 10.1016/j.pop.2016.04.012 PMID: 27545740
  65. Zainab R, Akram M, Daniyal M, Riaz M. Awareness and current therapeutics of asthma. Dose Response 2019; 17(3) doi: 10.1177/1559325819870900 PMID: 31523203
  66. Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders. Subst Abus 2016; 37(1): 20-4. doi: 10.1080/08897077.2015.1129388 PMID: 26848803
  67. Tesse R, Borrelli G, Mongelli G, Mastrorilli V, Cardinale F. Treating pediatric asthma according guidelines. Front Pediatr 2018; 6: 234. doi: 10.3389/fped.2018.00234 PMID: 30191146
  68. Lim TK. Corticosteroids in the emergency treatment of acute severe asthma. Chest 2000; 117(5): 1526-7. doi: 10.1378/chest.117.5.1526-a PMID: 10807855
  69. Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: Current status and future perspectives. Respir Care 2015; 60(3): 455-68. doi: 10.4187/respcare.03200 PMID: 25118311
  70. Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol 2017; 139(5): 1431-44. doi: 10.1016/j.jaci.2017.03.002 PMID: 28477722
  71. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124(6): 1210-6. doi: 10.1016/j.jaci.2009.09.021 PMID: 19910033
  72. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43(2): 343-73. doi: 10.1183/09031936.00202013 PMID: 24337046
  73. McKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med 2018; 378(10): 902-10. doi: 10.1056/NEJMoa1714257 PMID: 29504499
  74. Ducharme FM, Lemire C, Noya FJD, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009; 360(4): 339-53. doi: 10.1056/NEJMoa0808907 PMID: 19164187
  75. Harper GD, Neill P, Vathenen AS, Cookson JB, Ebden P. A comparison of inhaled beclomethasone dipropionateand nedocromil sodium as additional therapy in asthma. Respir Med 1990; 84(6): 463-9. doi: 10.1016/S0954-6111(08)80110-2 PMID: 2177216
  76. Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O’Byrne PM. The global initiative for asthma (GINA): 25 years later. Eur Respir J 2019; 54(2): 1900598. doi: 10.1183/13993003.00598-2019 PMID: 31273040
  77. Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy 2022; 77(4): 1105-13. doi: 10.1111/all.15076 PMID: 34478578
  78. Reddel HK, Bateman ED, Schatz M, Krishnan JA, Cloutier MM. A practical guide to implementing SMART in asthma management. J Allergy Clin Immunol Pract 2022; 10(1): S31-8. doi: 10.1016/j.jaip.2021.10.011 PMID: 34666208
  79. Garg R, Piplani M, Upadhayay A, Bhateja P. Correlation between demographic characteristics and degree of illness among asthmatic patients in the panchkula region. Eur Chem Bull 2023; 12((Special Issue 5)): 4868-74.
  80. Garg R, Piplani M, Singh Y, Bhateja P, Rana R. An overview of integrated risk factors with prevention and prevalence of asthma at the global level. Curr Tradit Med 2023; 10: e250523217358. doi: 10.2174/2215083810666230525153908
  81. Gottwalt B, Tadi P. Methylxanthines. StatPearls 2023.
  82. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182(7): 897-904. doi: 10.1164/rccm.200906-0937OC PMID: 20224070
  83. Cosío BG, Dacal D, Pérez de Llano L. Asthma-COPD overlap: Identification and optimal treatment. Ther Adv Respir Dis 2018; 12. doi: 10.1177/1753466618805662 PMID: 30336736
  84. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: Executive summary and rationale for key changes. Am J Respir Crit Care Med 2022; 205(1): 17-35. doi: 10.1164/rccm.202109-2205PP PMID: 34658302
  85. Clinical Practice Guidelines. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US) 2003.
  86. Möllmann H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol 1985; 29(1): 85-9. doi: 10.1007/BF00547374 PMID: 4054209
  87. Moy ML, Israel E, Weiss ST, Juniper EF, Dubé L, Drazen JM. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med 2001; 163(4): 924-9. doi: 10.1164/ajrccm.163.4.2008014 PMID: 11282767
  88. Vollmer WM, Markson L, O’Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999; 160(5): 1647-52. doi: 10.1164/ajrccm.160.5.9902098 PMID: 10556135
  89. Waalkens HJ, Van Essen-Zandvliet EE, Hughes MD, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993; 148(5): 1252-7. doi: 10.1164/ajrccm/148.5.1252 PMID: 8239161
  90. Cheng ZR, Tan YH, Teoh OH, Lee JH. Keeping pace with adolescent asthma: A practical approach to optimizing care. Pulm Ther 2022; 8(1): 123-37. doi: 10.1007/s41030-021-00177-2 PMID: 34743311
  91. Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF Jr, Pace W, Schatz M. Managing asthma in adolescents and adults: 2020 asthma guideline update from the national asthma education and prevention program. JAMA 2020; 324(22): 2301-17. doi: 10.1001/jama.2020.21974 PMID: 33270095
  92. Scarfone RJ, Teach SJ. Acute asthma exacerbations in children younger than 12 years: Emergency department management. Waltham, MA: UpToDate 2020.
  93. Ish P, Malhotra N, Gupta N. GINA 2020: What’s new and why? J Asthma 2021; 58(10): 1273-7. doi: 10.1080/02770903.2020.1788076 PMID: 32586146
  94. Desforges JF, Larsen GL. Asthma in children. N Engl J Med 1992; 326(23): 1540-5. doi: 10.1056/NEJM199206043262306 PMID: 1579137
  95. Martinez FD. Managing childhood asthma: Challenge of preventing exacerbations. Pediatrics 2009; 123 (Suppl. 3): S146-50. doi: 10.1542/peds.2008-2233D PMID: 19221157
  96. Quek JS, Tang WE, Chen E, Smith HE. Understanding the journeys of patients with an asthma exacerbation requiring urgent therapy at a primary care clinic. BMC Pulm Med 2022; 22(1): 231. doi: 10.1186/s12890-022-02024-9 PMID: 35710361
  97. Hay WW Jr, Deterding RR. Current diagnosis & treatment pediatrics. McGraw-Hill Education 2014.
  98. Fala L. Nucala (mepolizumab): First IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits 2016; 9((Spec Feature)): 106.
  99. Boulet LP, Becker A, Bérubé D, Beveridge R, Ernst P. Canadian asthma consensus report, 1999. CMAJ 1999; 161(11): S1-S61. PMID: 10906907
  100. Farooq J, Khaliq SA, Ghuman F, Shaikh J, Azhar I. Study on allopathic and alternative treatments of asthma and factors influencing treatment choices. Evid Based Complement Alternat Med 2022; 2022: 1-8. doi: 10.1155/2022/4699414 PMID: 36072402
  101. Baiardini I, Braido F, Brandi S, et al. The impact of GINA suggested drugs for the treatment of asthma on health-related quality of life: A GA 2 LEN review. Allergy 2008; 63(8): 1015-30. doi: 10.1111/j.1398-9995.2008.01823.x PMID: 18691305
  102. Vernon MK, Wiklund I, Bell JA, Dale P, Chapman KR. What do we know about asthma triggers? A review of the literature. J Asthma 2012; 49(10): 991-8. doi: 10.3109/02770903.2012.738268 PMID: 23574397
  103. Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: A report from the national asthma education and prevention program coordinating committee expert panel working group. J Allergy Clin Immunol 2020; 146(6): 1217-70. doi: 10.1016/j.jaci.2020.10.003 PMID: 33280709
  104. Holimon TD, Chafin CC, Self TH. Nocturnal asthma uncontrolled by inhaled corticosteroids: Theophylline or long-acting β2 agonists? Drugs 2001; 61(3): 391-418. doi: 10.2165/00003495-200161030-00007 PMID: 11293649

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers